CV:IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol IPA.
This company has cross-listed shares that trade in the U.S. as the symbol IPA.
6.65 CAD
As of 08/11/2022
Security Information
Category1: Global Equity
Category2: Common stocks
Category3: Developed markets ex-US
GICS sector: Communication Services
Industry: Biotechnology
Index country: Canada
Country of incorporation: Canada
IPO date: 01/01/1900
Stock exchange: TSX Venture Exchange
Exchange country: Canada
Market cap: 141,234,000 CAD
Current dividend yield: 0.00%
Sedol: